European Innovation Council

PrecisionLife is a company focused on advancing precision medicine by leveraging its proprietary artificial intelligence platform to enhance the understanding of chronic diseases. It specializes in patient stratification, which allows for the identification of novel subgroups within patient populations, thereby generating insights that inform the discovery of new drug targets and drug repositioning candidates. By utilizing unique and patentable biomarkers, PrecisionLife connects patients with specific disease sub-groups and potential therapies, ultimately aiming to create personalized treatment alternatives. The company’s innovative approach not only drives advancements in biopharmaceuticals but also seeks to improve patient outcomes, enabling individuals to lead longer and healthier lives.

AlzeCure Pharma AB is a pharmaceutical company based in Huddinge, Sweden, that specializes in developing drug therapies aimed at treating diseases affecting the central nervous system, with a particular emphasis on Alzheimer's disease. Established in 2012, the company is advancing multiple drug candidates through its research platforms, NeuroRestore and Alzstatin, among others. Current projects include ACD855, which is undergoing Phase I clinical trials for sleep disruptions, traumatic brain injuries, and Alzheimer's disease, along with several other candidates targeting Alzheimer's: ACD856, ACD679, and ACD680. Additionally, AlzeCure is developing ACD857 for eye and ear conditions, and VR1 for neuropathic pain, alongside TrkA-NAM for osteoarthritic pain. Through its focused research initiatives, AlzeCure Pharma aims to address significant unmet medical needs in neurodegenerative diseases.

Elicera Therapeutics is a clinical-stage immuno-oncology company based in Sweden that focuses on developing innovative cell and gene therapies to treat cancer. The company’s portfolio includes four drug candidates: two oncolytic virus therapies, ELC-100 and ELC-201, and two CAR T-cell treatments, ELC-301 and ELC-401. Additionally, Elicera has developed a universal CAR T-cell technology platform named iTANK (ELC-001), designed to enhance the efficacy of CAR T-cell therapies by enabling a multi-targeted approach against solid tumors. With its commitment to advancing immune-based cancer treatments, Elicera Therapeutics aims to improve outcomes for patients facing various forms of cancer.

Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable knowledge for various sectors including academic research, plant and animal breeding, and biomedicine. Sequentia serves a diverse client base of over 30 public and private research centers, companies, and hospitals, participating in more than 160 R&D projects. The company offers cloud software, custom software, and bioinformatics consulting services, with notable contributions such as two open-source biodata banks and an award-winning R&D line called Tricopharming, established in 2014. Sanseverino and Aiese have published over 40 scientific articles in high-impact journals, underscoring the company's expertise in omics sciences.

Oryl Photonics specializes in developing laboratory instruments for pharmaceutical and biotech companies. Their core product provides a simple, reliable, and cost-effective method for measuring solubility, contributing to accelerated drug development and improved medicine. The company's unique technology preserves valuable substances during testing, offering a solubility measurement service that empowers researchers to make data-driven decisions and expedite product development.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

ResoTher Pharma is a privately held biotechnology company based in Copenhagen, Denmark. The company specializes in developing peptide-based drugs derived from Annexin A1, an endogenous immunomodulator. These drugs are designed as resolution therapies for diseases where neutrophil-driven inflammation is a key pathological factor. ResoTher Pharma's primary focus is on addressing cardiovascular and inflammatory disorders that have significant unmet medical needs. Their patented peptide drugs target a G-protein coupled receptor expressed on leukocytes, aiming to mimic the body's natural response to resolving inflammation and promoting tissue repair.

Epigene Labs SAS is a biotechnology firm focused on enhancing precision oncology through its advanced technology platform that utilizes artificial intelligence. Founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, the company addresses the significant challenges of aggregating, analyzing, and visualizing extensive genomic data in cancer research. By integrating proprietary data from partners with publicly available datasets, Epigene Labs provides medical researchers with actionable insights and user-friendly analytics. The company collaborates with leading cancer centers and prominent biotech firms to develop intelligence-augmenting services that support drug discovery and research in precision oncology. Its innovative approach aims to transform genomic data into effective strategies for targeted cancer therapies.

Pulse is a platform for furthering our understanding of bioprinting and its applications in space exploration and medicine.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Aviwell is a company focused on enhancing animal health and growth through the development of natural and sustainable solutions. Utilizing a microbiota-based platform powered by artificial intelligence and machine learning, Aviwell operates at the intersection of digital and life sciences. The company aims to provide insights that improve animal health and performance while addressing the agri-food industry's challenges in sustainably feeding a growing global population. By prioritizing health and sustainability, Aviwell seeks to offer effective solutions at a reduced cost, ultimately contributing to better nourishment for the planet.

Cellbox Solutions is a technology company that specializes in innovative logistic solutions for the global BioMed industry. It has developed a carbon dioxide incubator designed for the storage, isolation, handling, and analysis of biological materials. This incubator offers essential logistic services and ensures the proper handling of living cells, facilitating their storage, reproduction, transportation, and analysis. By enabling the transportation of living cells via various methods, including road, rail, and air, Cellbox Solutions supports healthcare providers in their efforts to deliver the latest therapies to patients.

Arthex Biotech S.L. is a biotechnology company founded in 2019 and based in Paterna, Spain. It specializes in the development of antisense RNA treatments specifically aimed at addressing genetic diseases and disorders where microRNAs play a significant role. As a spin-off from the University of Valencia, Arthex Biotech leverages a strong foundation in drug discovery and has a team comprising experts with extensive experience in neuromuscular diseases. The company focuses on creating innovative therapies for conditions with unmet medical needs, providing new treatment options for patients suffering from rare genetic diseases and other high-need medical issues. With guidance from esteemed scientific and clinical advisors, Arthex Biotech is committed to advancing its product development to improve patient outcomes.

Abbelight is a company specializing in super-resolution microscopy, specifically through its innovative single molecule localization microscopy technology. This technology integrates consumables, hardware, and software to deliver state-of-the-art solutions for biological research, enhancing the ability to observe biological samples with superior resolution. By focusing on simplifying the use of advanced microscopy techniques, Abbelight aims to make these cutting-edge tools accessible to a wide range of laboratories without compromising performance. The company supports scientists throughout their research process, from sample preparation to result analysis, by offering expertise in chemistry, computer science, and optical instrumentation. Abbelight's commitment is to empower researchers in biology, pharmacology, and environmental science with reliable and advanced imaging capabilities.

Inobiostar focuses on research and experimental development services.

Samplix is a biotechnology company based in Herlev, Denmark, that specializes in advanced sample preparation for single DNA and RNA molecules. The company has developed the proprietary Xdrop™ technology, which utilizes a unique "water-oil-water" droplet formation to create millions of reaction chambers for handling individual DNA molecules. This innovative technology allows for targeted enrichment of large DNA fragments, addressing the limitations of existing multi-molecule preparation methods. By enabling precise and sensitive sample preparation, Samplix empowers researchers to conduct more informed studies, facilitating the sequencing of genetic regions critical for understanding virus integration and minimizing unintended CRISPR edits. The Xdrop™ system includes both the instrumentation and consumables needed for effective single-molecule analysis, thereby enhancing the ease of use and efficiency in molecular research.

Samplix is a biotechnology company based in Herlev, Denmark, that specializes in advanced sample preparation for single DNA and RNA molecules. The company has developed the proprietary Xdrop™ technology, which utilizes a unique "water-oil-water" droplet formation to create millions of reaction chambers for handling individual DNA molecules. This innovative technology allows for targeted enrichment of large DNA fragments, addressing the limitations of existing multi-molecule preparation methods. By enabling precise and sensitive sample preparation, Samplix empowers researchers to conduct more informed studies, facilitating the sequencing of genetic regions critical for understanding virus integration and minimizing unintended CRISPR edits. The Xdrop™ system includes both the instrumentation and consumables needed for effective single-molecule analysis, thereby enhancing the ease of use and efficiency in molecular research.

Smart Immune is a clinical-stage biotechnology company dedicated to advancing hematopoietic stem cell-based biotherapies aimed at improving the prognosis and quality of life for patients with severe diseases. The company's primary focus is on its innovative cell therapy program that utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This program is complemented by integrative developments in targeted conditioning, gene therapy, and genome editing, allowing for the creation of next-generation treatments. Smart Immune's approach aims to provide effective allogeneic T-cell therapies for patients suffering from life-threatening conditions, particularly hematological malignancies and primary immune deficiencies.

Smart Immune is a clinical-stage biotechnology company dedicated to advancing hematopoietic stem cell-based biotherapies aimed at improving the prognosis and quality of life for patients with severe diseases. The company's primary focus is on its innovative cell therapy program that utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This program is complemented by integrative developments in targeted conditioning, gene therapy, and genome editing, allowing for the creation of next-generation treatments. Smart Immune's approach aims to provide effective allogeneic T-cell therapies for patients suffering from life-threatening conditions, particularly hematological malignancies and primary immune deficiencies.

Inbiome is a trailblazing company in molecular diagnostics, specializing in proprietary molecular culture technology. This innovation enables swift bacterial testing and microbiome analysis, significantly expediting the process compared to traditional methods. The company's primary mission is to advance clinical microbiology by focusing on microbial detection and product development, thereby guiding clinicians towards more accurate and timely diagnoses. By offering advanced molecular technology for microbiome analysis, Inbiome aids in enhancing the understanding of bacteria in the human body, facilitating correct treatments, and mitigating unnecessary complications, costs, and anti-microbial resistance.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

Iris.ai is a company that offers an AI-driven science assistant designed to enhance research and development efforts in various sectors, including corporate and academic environments. Its RSpace solution features advanced capabilities such as smart search, a variety of filters, reading list analysis, auto-generated summaries, and autonomous data extraction and systematization. By leveraging natural language processing algorithms, Iris.ai aims to improve the efficiency and innovation of corporate R&D by providing tools that facilitate the tracking of factuality in scientific texts. This platform empowers research teams to conduct secondary scientific research more effectively, enabling them to access and analyze the latest scientific insights that exceed traditional human capabilities.

Iris.ai is a company that offers an AI-driven science assistant designed to enhance research and development efforts in various sectors, including corporate and academic environments. Its RSpace solution features advanced capabilities such as smart search, a variety of filters, reading list analysis, auto-generated summaries, and autonomous data extraction and systematization. By leveraging natural language processing algorithms, Iris.ai aims to improve the efficiency and innovation of corporate R&D by providing tools that facilitate the tracking of factuality in scientific texts. This platform empowers research teams to conduct secondary scientific research more effectively, enabling them to access and analyze the latest scientific insights that exceed traditional human capabilities.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of both rare and common diseases. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the risks associated with traditional drug development while significantly reducing the costs and time required to bring effective treatments to patients. With over 20 years of expertise in international genomics research, Arctic Therapeutics employs an innovative methodology in its drug development efforts. Collaborating closely with the Center for Applied Genomics at the Children's Hospital of Philadelphia, the company is actively involved in repurposing and developing breakthrough medical treatments. Notably, Arctic Therapeutics is working on a drug candidate for Alzheimer’s disease that has the potential to become the first cure for dementia, addressing both treatment and prevention. The company was inspired by Dr. Hakon Hakonarson, a prominent figure in applied genomics, whose work has been recognized as pioneering in the field of genetic research and therapeutic development.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of both rare and common diseases. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the risks associated with traditional drug development while significantly reducing the costs and time required to bring effective treatments to patients. With over 20 years of expertise in international genomics research, Arctic Therapeutics employs an innovative methodology in its drug development efforts. Collaborating closely with the Center for Applied Genomics at the Children's Hospital of Philadelphia, the company is actively involved in repurposing and developing breakthrough medical treatments. Notably, Arctic Therapeutics is working on a drug candidate for Alzheimer’s disease that has the potential to become the first cure for dementia, addressing both treatment and prevention. The company was inspired by Dr. Hakon Hakonarson, a prominent figure in applied genomics, whose work has been recognized as pioneering in the field of genetic research and therapeutic development.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

Enduro Genetics is a technology provider that specializes in enhancing large-scale fermentations through its proprietary synthetic biology technology. The company focuses on improving the performance of fermentation processes by developing a genetic plugin technology that is free of antibiotic resistance genes. This innovation allows for higher yields by enriching spontaneous high producers within the fermentation population, facilitating the production of complex or cellular inhibit products by addressing strain instability. By maximizing the performance of cells derived from production strains, Enduro aims to bolster the competitiveness of both current and future green bioproduction initiatives.

Xenikos is a biopharmaceutical company focused on developing innovative immunotherapy treatments aimed at restoring health to patients suffering from serious immune diseases and transplant rejection. The company specializes in creating anti-T-cell antibodies that act as a therapeutic tool to reset the immune system. Once administered, these antibodies specifically target and eliminate activated adult T cells, allowing for improved treatment outcomes in various medical conditions. By harnessing the potential of antibody action, Xenikos aims to provide efficient solutions that can significantly enhance patient recovery and overall well-being.

Elicit Plant is an agro-biotech company focused on enhancing crops' resilience to water stress and developing innovative phytosterol-based solutions. By utilizing proprietary technology, the company aims to improve plant stress resistance and activate their natural defenses, addressing the global challenges posed by climate change in agriculture. Extensive field trials conducted across three continents have shown that Elicit Plant's biosolutions are effective, providing farmers with consistent and substantial returns on investment. Through its advancements, Elicit Plant seeks to lead the ecological transition in agriculture, ensuring that crops are better equipped to handle water shortages and contribute to sustainable farming practices.

Herantis Pharma is a biotech company focused on addressing unmet clinical needs, particularly in the field of neurodegenerative diseases. The company's primary development program centers on HER-096, a peptidomimetic molecule designed to mimic the biological activity of the neuroprotective CDNF protein. By targeting Parkinson's disease, Herantis Pharma aims to develop disease-modifying therapies that could significantly improve patient outcomes.

Herantis Pharma is a biotech company focused on addressing unmet clinical needs, particularly in the field of neurodegenerative diseases. The company's primary development program centers on HER-096, a peptidomimetic molecule designed to mimic the biological activity of the neuroprotective CDNF protein. By targeting Parkinson's disease, Herantis Pharma aims to develop disease-modifying therapies that could significantly improve patient outcomes.

Actome is a biotechnology company that specializes in the development of advanced interactome technology aimed at enhancing life science research and personalized medicine. The firm employs a proprietary method that allows for the detection of single protein molecules and their interaction complexes. This technology translates the status of proteins into DNA barcodes through the use of DNA-labeled antibodies, facilitating detailed molecular biological research. Actome's innovations enable clients to analyze protein quantification, interactions, and post-translational modifications within biological samples, thereby contributing to advancements in pharmaceuticals and tailored therapeutic solutions.

FOx Biosystems is a biotechnology company focused on enhancing biomolecular interaction analysis for life science research and industry. Founded in 2017 by Filip Delport and Jeroen Lammertyn, and based in Temse, Oost-Vlaanderen, Belgium, the company specializes in developing custom applications, including probes and devices, to support various research needs. FOx Biosystems employs real-time, label-free analysis technology that offers significant advantages over traditional biomolecular analysis tools, such as ease of use, speed, and cost-effectiveness. This technology enables healthcare companies and researchers to obtain high-quality biomolecular data, including concentration measurements, affinity data, and kinetic data, ultimately aiming to transform the life sciences sector.

Cherry Biotech is a biomedical technology company specializing in Organ on Chip systems that facilitate drug discovery and personalized medicine. The company focuses on developing microfluidic technology that allows for the culture and simulation of human organs under various physiological and pathological conditions. Cherry Biotech also provides temperature controllers for rapid temperature adjustments and next-generation 3D cell culture technologies. These innovations assist clinicians in accurately recapitulating the human cellular microenvironment, which is crucial for drug development and toxicity assessment.

Arthex Biotech S.L. is a biotechnology company founded in 2019 and based in Paterna, Spain. It specializes in the development of antisense RNA treatments specifically aimed at addressing genetic diseases and disorders where microRNAs play a significant role. As a spin-off from the University of Valencia, Arthex Biotech leverages a strong foundation in drug discovery and has a team comprising experts with extensive experience in neuromuscular diseases. The company focuses on creating innovative therapies for conditions with unmet medical needs, providing new treatment options for patients suffering from rare genetic diseases and other high-need medical issues. With guidance from esteemed scientific and clinical advisors, Arthex Biotech is committed to advancing its product development to improve patient outcomes.

Arthex Biotech S.L. is a biotechnology company founded in 2019 and based in Paterna, Spain. It specializes in the development of antisense RNA treatments specifically aimed at addressing genetic diseases and disorders where microRNAs play a significant role. As a spin-off from the University of Valencia, Arthex Biotech leverages a strong foundation in drug discovery and has a team comprising experts with extensive experience in neuromuscular diseases. The company focuses on creating innovative therapies for conditions with unmet medical needs, providing new treatment options for patients suffering from rare genetic diseases and other high-need medical issues. With guidance from esteemed scientific and clinical advisors, Arthex Biotech is committed to advancing its product development to improve patient outcomes.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

Celeris Therapeutics is an AI-first drug discovery company that focuses on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address high unmet medical needs in diseases like Parkinson's and various cancers. The company has created the Celeris One platform, which utilizes structure-based geometric deep learning to enhance the design and development of degraders by prioritizing specific E3 ligases, designing effective linkers, and selecting optimal compounds for synthesis. Additionally, Celeris Therapeutics operates an in-house automated laboratory that facilitates rapid generation of experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to discover and develop small-molecule degrader therapies across multiple therapeutic areas, while also advancing its own internal drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

Immunethep is a biotechnology company specializing in the development of immunotherapies for immune system-related diseases. Originating as a spin-off from the University of Porto, the company has leveraged its proprietary technology to uncover a novel mechanism by which various pathogenic bacteria inhibit the host immune response. This discovery enables Immunethep to create broad-spectrum anti-bacterial immunotherapies. Among its initiatives, the company is developing neonatal vaccines aimed at protecting infants from bacterial infections while still in the womb, allowing for the enhancement of immunity and prevention of multi-bacterial infections. Through its innovative approach, Immunethep addresses significant unmet medical needs in the realm of infectious diseases.

Immunethep is a biotechnology company specializing in the development of immunotherapies for immune system-related diseases. Originating as a spin-off from the University of Porto, the company has leveraged its proprietary technology to uncover a novel mechanism by which various pathogenic bacteria inhibit the host immune response. This discovery enables Immunethep to create broad-spectrum anti-bacterial immunotherapies. Among its initiatives, the company is developing neonatal vaccines aimed at protecting infants from bacterial infections while still in the womb, allowing for the enhancement of immunity and prevention of multi-bacterial infections. Through its innovative approach, Immunethep addresses significant unmet medical needs in the realm of infectious diseases.

Elicit Plant is an agro-biotech company focused on enhancing crops' resilience to water stress and developing innovative phytosterol-based solutions. By utilizing proprietary technology, the company aims to improve plant stress resistance and activate their natural defenses, addressing the global challenges posed by climate change in agriculture. Extensive field trials conducted across three continents have shown that Elicit Plant's biosolutions are effective, providing farmers with consistent and substantial returns on investment. Through its advancements, Elicit Plant seeks to lead the ecological transition in agriculture, ensuring that crops are better equipped to handle water shortages and contribute to sustainable farming practices.

Actome is a biotechnology company that specializes in the development of advanced interactome technology aimed at enhancing life science research and personalized medicine. The firm employs a proprietary method that allows for the detection of single protein molecules and their interaction complexes. This technology translates the status of proteins into DNA barcodes through the use of DNA-labeled antibodies, facilitating detailed molecular biological research. Actome's innovations enable clients to analyze protein quantification, interactions, and post-translational modifications within biological samples, thereby contributing to advancements in pharmaceuticals and tailored therapeutic solutions.

AcouSort AB is a Swedish company focused on developing and selling laboratory products and integrated OEM solutions that utilize ultrasound technology for the separation, washing, and enrichment of biological particles such as cells and exosomes. The company specializes in automated sample preparation for researchers and life science firms, leveraging acoustofluidics technology derived from research at Lund University's Department of Biomedical Engineering. AcouSort's product offerings include AcouTrap, which isolates microscopic particles, AcouWash for washing samples, and AcouPlasma, designed for plasma separation. Through its innovative solutions, AcouSort aims to enhance research and diagnostic processes in the life sciences sector.

Ovagen is a biotechnology company specializing in the production of germ-free (GF) chicken eggs and GF birds in commercial quantities, primarily for the pharmaceutical industry. The company has developed a unique process that enables large-scale production of recombinant proteins to Good Manufacturing Practice (GMP) standards using a transgenic chicken platform. This innovative approach provides pharmaceutical companies with a biosecure, flexible, and cost-effective biomanufacturing solution for vaccines and therapeutic proteins. In addition to its core production capabilities, Ovagen offers Contract Research Services and possesses extensive expertise in specific poultry and rodent research technologies, as well as in the housing and husbandry of specific pathogen-free (SPF) poultry and rodents.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

Metafora Biosystems is a biotechnology company focused on developing innovative and unmatched ligands known as receptor-binding domains (RBDs) for nutrient transporters. These tools enable the detection of subtle quantitative changes in cell physiology, reflecting metabolic variations caused by factors such as drugs, genetic mutations, cell culture conditions, and diseases. The company's technology offers multiple competitive advantages across various segments of the biomarker market, positioning it as a valuable player in the field of metabolic research and diagnostics.

Aviwell is a company focused on enhancing animal health and growth through the development of natural and sustainable solutions. Utilizing a microbiota-based platform powered by artificial intelligence and machine learning, Aviwell operates at the intersection of digital and life sciences. The company aims to provide insights that improve animal health and performance while addressing the agri-food industry's challenges in sustainably feeding a growing global population. By prioritizing health and sustainability, Aviwell seeks to offer effective solutions at a reduced cost, ultimately contributing to better nourishment for the planet.

PhosPrint, established in 2019 and headquartered in Agia Paraskevi, Attiki, specializes in laser bioprinting systems and regenerative medicine. The company's core business involves developing and providing on-site cell printing during surgeries, aiming to facilitate tissue regeneration and advance medical research. PhosPrint's offerings include healthcare technology products that leverage laser bioprinting and biotechnology research, enabling researchers and medical professionals to access innovative tools and procedures to combat diseases and medical conditions.

Metafora Biosystems is a biotechnology company focused on developing innovative and unmatched ligands known as receptor-binding domains (RBDs) for nutrient transporters. These tools enable the detection of subtle quantitative changes in cell physiology, reflecting metabolic variations caused by factors such as drugs, genetic mutations, cell culture conditions, and diseases. The company's technology offers multiple competitive advantages across various segments of the biomarker market, positioning it as a valuable player in the field of metabolic research and diagnostics.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

Celeris Therapeutics is an AI-first drug discovery company that focuses on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address high unmet medical needs in diseases like Parkinson's and various cancers. The company has created the Celeris One platform, which utilizes structure-based geometric deep learning to enhance the design and development of degraders by prioritizing specific E3 ligases, designing effective linkers, and selecting optimal compounds for synthesis. Additionally, Celeris Therapeutics operates an in-house automated laboratory that facilitates rapid generation of experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to discover and develop small-molecule degrader therapies across multiple therapeutic areas, while also advancing its own internal drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

Qubit Pharmaceuticals is a Paris-based company established in 2020, focusing on innovative technology for pharmaceutical drug discovery. Founded by prominent academic institutions and researchers, including CNAM, CNRS, the University of Texas at Austin, Sorbonne University, and Washington University, the company leverages over 20 years of research and development. Qubit Pharmaceuticals has developed a drug discovery simulation platform that aims to significantly reduce the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, the platform facilitates virtual screening and visualization of potential drug candidates. By integrating principles of quantum physics, Qubit Pharmaceuticals supports biopharmaceutical companies in accelerating their research and development processes, ultimately enhancing the efficiency of drug discovery.

Elicera Therapeutics is a clinical-stage immuno-oncology company based in Sweden that focuses on developing innovative cell and gene therapies to treat cancer. The company’s portfolio includes four drug candidates: two oncolytic virus therapies, ELC-100 and ELC-201, and two CAR T-cell treatments, ELC-301 and ELC-401. Additionally, Elicera has developed a universal CAR T-cell technology platform named iTANK (ELC-001), designed to enhance the efficacy of CAR T-cell therapies by enabling a multi-targeted approach against solid tumors. With its commitment to advancing immune-based cancer treatments, Elicera Therapeutics aims to improve outcomes for patients facing various forms of cancer.

Core Biogenesis is a biotechnology company based in Paris, France, founded in 2020. It specializes in developing next-generation recombinant protein production technologies that utilize proprietary gene editing and plant biotechnology. The company aims to significantly lower the cost of producing growth factors, which are essential molecules used in the clean meat and cell therapy industries. Core Biogenesis employs an ultra-scalable bioproduction as a service (UBaaS) platform, allowing for the efficient mass production of valuable bioproducts by using plants as biofactories. This innovative approach enhances the speed and scalability of molecule extraction while enabling clients in the healthcare sector to improve cell growth, division, and survival, ultimately increasing yields and reducing costs.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Perha Pharmaceuticals is a biotechnology company dedicated to the research and development of innovative therapies, particularly focusing on kinase inhibitors. The company explores natural marine substances as a foundation for its drug discovery efforts, optimizing molecules derived from marine organisms. Perha Pharmaceuticals aims to address significant medical challenges, including the prevention of cisplatin-induced hearing loss and the treatment of cognitive disorders associated with Down syndrome and Alzheimer's disease. Through its targeted approach, the company seeks to provide effective solutions for patients suffering from hearing loss and related cognitive impairments.

Ovagen is a biotechnology company specializing in the production of germ-free (GF) chicken eggs and GF birds in commercial quantities, primarily for the pharmaceutical industry. The company has developed a unique process that enables large-scale production of recombinant proteins to Good Manufacturing Practice (GMP) standards using a transgenic chicken platform. This innovative approach provides pharmaceutical companies with a biosecure, flexible, and cost-effective biomanufacturing solution for vaccines and therapeutic proteins. In addition to its core production capabilities, Ovagen offers Contract Research Services and possesses extensive expertise in specific poultry and rodent research technologies, as well as in the housing and husbandry of specific pathogen-free (SPF) poultry and rodents.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

Core Biogenesis is a biotechnology company based in Paris, France, founded in 2020. It specializes in developing next-generation recombinant protein production technologies that utilize proprietary gene editing and plant biotechnology. The company aims to significantly lower the cost of producing growth factors, which are essential molecules used in the clean meat and cell therapy industries. Core Biogenesis employs an ultra-scalable bioproduction as a service (UBaaS) platform, allowing for the efficient mass production of valuable bioproducts by using plants as biofactories. This innovative approach enhances the speed and scalability of molecule extraction while enabling clients in the healthcare sector to improve cell growth, division, and survival, ultimately increasing yields and reducing costs.

BrainEver is a medical research company focused on developing innovative drugs for neurodegenerative disorders. Building on research by Alain Prochiantz and his team, BrainEver investigates the role of homeoproteins, which are essential for brain development and ongoing neuronal functions. The company hypothesizes that administering homeoproteins can enhance the physiological resilience of neurons and improve clinical symptoms in patients. Among its drug candidates, Engrailed 1 (BREN01) is the most advanced, aimed at treating Parkinson Disease and Amyotrophic Lateral Sclerosis (ALS). Additionally, BrainEver is actively developing a pipeline of four more drug candidates targeting other neurodegenerative conditions, including Huntington Disease and Optic Neuropathies. Through its research and development efforts, BrainEver seeks to provide effective therapeutic options for healthcare practitioners and their patients.

Computomics GmbH is a bioinformatics company based in Tübingen, Germany, specializing in molecular data analysis for crop biotechnology and agricultural research. Founded in 2012, the company employs advanced artificial intelligence and machine learning techniques to provide a range of services, including genome assembly, transcriptome studies, and genomic selection. Computomics focuses on analyzing complex plant genomes, offering solutions such as differential gene expression analysis, reference-free genotyping, and DNA methylation analysis. Its interactive visualization tools empower researchers to make data-driven decisions while ensuring thorough analysis and comprehensive reporting of genomic data. With a diverse team of experts in machine learning, biology, and bioinformatics, Computomics has successfully completed over 190 projects, facilitating sustainable agricultural development and aiding in the advancement of global food security.

Core Biogenesis is a biotechnology company based in Paris, France, founded in 2020. It specializes in developing next-generation recombinant protein production technologies that utilize proprietary gene editing and plant biotechnology. The company aims to significantly lower the cost of producing growth factors, which are essential molecules used in the clean meat and cell therapy industries. Core Biogenesis employs an ultra-scalable bioproduction as a service (UBaaS) platform, allowing for the efficient mass production of valuable bioproducts by using plants as biofactories. This innovative approach enhances the speed and scalability of molecule extraction while enabling clients in the healthcare sector to improve cell growth, division, and survival, ultimately increasing yields and reducing costs.

Camino Science is a biotech company based in Bialystok, Poland, specializing in molecular biology research and the development of innovative biotech tools. The company integrates artificial intelligence into its offerings to support scientific inquiry and advance research capabilities. By focusing on the intersection of biotechnology and technology, Camino Science aims to enhance the efficiency and effectiveness of scientific exploration in various biological fields.

Nagi Bioscience SA is a Swiss company based in Lausanne that specializes in developing and manufacturing an innovative automated testing device utilizing organism-on-chip technology. This device leverages the microscopic worm Caenorhabditis elegans for in vivo testing, enabling pharmaceutical, chemical, and cosmetic companies to assess the toxic and beneficial effects of various substances. By integrating fully automated in vitro handling, culture, and analysis, Nagi Bioscience's platform facilitates toxicity testing, drug discovery, and anthelmintic testing. This approach allows clients to evaluate comprehensive biological responses that can only be observed at the level of the whole organism, thereby transforming traditional testing methodologies.

Betalin Therapeutics is a privately-held company dedicated to developing innovative cell therapy solutions for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. This platform combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. The EMP aims to offer an alternative to traditional insulin therapy, potentially eliminating the need for insulin injections and glucose monitoring in patients. Following promising in-vitro and preliminary in-vivo results, Betalin Therapeutics is focused on optimizing the therapy using animal models and preparing to submit an Investigational New Drug (IND) application to the FDA in anticipation of advancing to clinical trials.

VBL Therapeutics is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel treatments for cancer and immune-inflammatory diseases. The company utilizes two proprietary platform technologies that harness the body's natural physiological and genetic regulatory elements. Its lead product candidate, VB-111, is a gene-based biologic aimed at treating solid tumors, specifically recurrent glioblastoma, an aggressive form of brain cancer. In addition to its oncology efforts, VBL Therapeutics is pursuing programs that target anti-inflammatory diseases, leveraging its Lecinoxoid platform technology. The company's diverse portfolio reflects its commitment to advancing innovative therapeutic solutions in the biopharmaceutical landscape.

VBL Therapeutics is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel treatments for cancer and immune-inflammatory diseases. The company utilizes two proprietary platform technologies that harness the body's natural physiological and genetic regulatory elements. Its lead product candidate, VB-111, is a gene-based biologic aimed at treating solid tumors, specifically recurrent glioblastoma, an aggressive form of brain cancer. In addition to its oncology efforts, VBL Therapeutics is pursuing programs that target anti-inflammatory diseases, leveraging its Lecinoxoid platform technology. The company's diverse portfolio reflects its commitment to advancing innovative therapeutic solutions in the biopharmaceutical landscape.

Perha Pharmaceuticals is a biotechnology company dedicated to the research and development of innovative therapies, particularly focusing on kinase inhibitors. The company explores natural marine substances as a foundation for its drug discovery efforts, optimizing molecules derived from marine organisms. Perha Pharmaceuticals aims to address significant medical challenges, including the prevention of cisplatin-induced hearing loss and the treatment of cognitive disorders associated with Down syndrome and Alzheimer's disease. Through its targeted approach, the company seeks to provide effective solutions for patients suffering from hearing loss and related cognitive impairments.

EVerZom is a nanomedicine biotech company based in Paris, France, that specializes in the large-scale manufacturing of extracellular vesicles, including exosomes, microvesicles, and apoptotic bodies. Founded in 2019, the company has developed a proprietary bioproduction platform that complies with Good Manufacturing Practice (GMP) standards, aimed at pharmaceutical companies. EVerZom's technology focuses on producing extracellular vesicles for applications in regenerative medicine and drug delivery, leveraging their protective and reparative properties. This innovative approach provides healthcare professionals with a valuable therapeutic tool to address organ failure and restore function and homeostasis in patients.

Computomics GmbH is a bioinformatics company based in Tübingen, Germany, specializing in molecular data analysis for crop biotechnology and agricultural research. Founded in 2012, the company employs advanced artificial intelligence and machine learning techniques to provide a range of services, including genome assembly, transcriptome studies, and genomic selection. Computomics focuses on analyzing complex plant genomes, offering solutions such as differential gene expression analysis, reference-free genotyping, and DNA methylation analysis. Its interactive visualization tools empower researchers to make data-driven decisions while ensuring thorough analysis and comprehensive reporting of genomic data. With a diverse team of experts in machine learning, biology, and bioinformatics, Computomics has successfully completed over 190 projects, facilitating sustainable agricultural development and aiding in the advancement of global food security.

enGenome is a bioinformatics company focused on enhancing the diagnosis and treatment of genetic diseases through its advanced genomic interpretation and bioinformatics software. By automating variant interpretation guidelines, the company reduces the occurrence of variants of uncertain significance and provides comprehensive reports that include supporting evidence. This technology enables geneticists to accurately and swiftly identify pathogenic genomic variants, ultimately leading to improved patient outcomes. Through its omics-based reporting, enGenome aims to assist physicians in making informed decisions regarding diagnosis and therapies, thereby contributing to more effective healthcare solutions.

LiMM Therapeutics is a biopharmaceutical company focused on developing innovative therapeutic agents aimed at preserving health and addressing inflammatory, infectious, and metabolic diseases. The company leverages the molecular interactions between neuronal cells and innate lymphoid cells to create products that regulate immune responses and combat infections. By bridging advancements in neural sensing and immunology, LiMM Therapeutics aims to unlock new therapeutic solutions that can significantly benefit patients. Its research emphasizes the neuronal-derived regulation of immune cell activity within peripheral tissues, contributing to the development of a robust pipeline of novel treatments.

Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable knowledge for various sectors including academic research, plant and animal breeding, and biomedicine. Sequentia serves a diverse client base of over 30 public and private research centers, companies, and hospitals, participating in more than 160 R&D projects. The company offers cloud software, custom software, and bioinformatics consulting services, with notable contributions such as two open-source biodata banks and an award-winning R&D line called Tricopharming, established in 2014. Sanseverino and Aiese have published over 40 scientific articles in high-impact journals, underscoring the company's expertise in omics sciences.

Next Generation Sensors is a biotech business that creates mass spectrometers for commercial uses in the life sciences. Finding rapid, accurate screening information for potential health, security, and environmental hazards relies on. By bringing the lab to the sample with portable, sensitive, accurate, and user-friendly technology for quick detection of dangerous compounds in our food, bodies, and environment, offers answers for a safer future.

Adivo GmbH is a veterinary biotechnology company based in Planegg, Germany, that focuses on developing species-specific therapeutic antibodies for companion animals, particularly dogs. The company aims to address serious diseases in pets while also exploring the potential for therapies applicable to other species. Adivo utilizes a new, fully synthetic, dog-specific drug library to isolate antibodies with optimal properties through phage display technology. The team at Adivo brings extensive experience from the development of human therapeutic antibodies, leveraging this expertise to innovate within the field of veterinary medicine. As a spin-off of MorphoSys AG, Adivo is positioned to advance therapeutic options for pets, contributing to improved health outcomes in companion animals.

Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable knowledge for various sectors including academic research, plant and animal breeding, and biomedicine. Sequentia serves a diverse client base of over 30 public and private research centers, companies, and hospitals, participating in more than 160 R&D projects. The company offers cloud software, custom software, and bioinformatics consulting services, with notable contributions such as two open-source biodata banks and an award-winning R&D line called Tricopharming, established in 2014. Sanseverino and Aiese have published over 40 scientific articles in high-impact journals, underscoring the company's expertise in omics sciences.

Adivo GmbH is a veterinary biotechnology company based in Planegg, Germany, that focuses on developing species-specific therapeutic antibodies for companion animals, particularly dogs. The company aims to address serious diseases in pets while also exploring the potential for therapies applicable to other species. Adivo utilizes a new, fully synthetic, dog-specific drug library to isolate antibodies with optimal properties through phage display technology. The team at Adivo brings extensive experience from the development of human therapeutic antibodies, leveraging this expertise to innovate within the field of veterinary medicine. As a spin-off of MorphoSys AG, Adivo is positioned to advance therapeutic options for pets, contributing to improved health outcomes in companion animals.

Epigene Labs SAS is a biotechnology firm focused on enhancing precision oncology through its advanced technology platform that utilizes artificial intelligence. Founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, the company addresses the significant challenges of aggregating, analyzing, and visualizing extensive genomic data in cancer research. By integrating proprietary data from partners with publicly available datasets, Epigene Labs provides medical researchers with actionable insights and user-friendly analytics. The company collaborates with leading cancer centers and prominent biotech firms to develop intelligence-augmenting services that support drug discovery and research in precision oncology. Its innovative approach aims to transform genomic data into effective strategies for targeted cancer therapies.

Aviwell is a company focused on enhancing animal health and growth through the development of natural and sustainable solutions. Utilizing a microbiota-based platform powered by artificial intelligence and machine learning, Aviwell operates at the intersection of digital and life sciences. The company aims to provide insights that improve animal health and performance while addressing the agri-food industry's challenges in sustainably feeding a growing global population. By prioritizing health and sustainability, Aviwell seeks to offer effective solutions at a reduced cost, ultimately contributing to better nourishment for the planet.

RemedyBio is an immunology-focused discovery and development company located in Dublin, Ireland. The company specializes in creating therapeutics aimed at enhancing immunotherapies for complex and heterogeneous diseases. RemedyBio has pioneered innovative techniques for understanding the immune system, particularly through its advanced discovery technology that accelerates the speed and scale of single-cell analysis. This technology supports next-generation applications in areas such as immuno-oncology, autoimmune diseases, and infectious diseases, ultimately offering the healthcare industry effective therapeutic and diagnostic solutions.

Synovance is a company focused on the bio-based economy, utilizing plant-derived resources to create a variety of products, including fuels, chemicals, materials, food, and feed. The company specializes in the development of bio-produced textile dyes and engineered organisms that can efficiently convert biomass into these essential materials. By creating customized strains and secondary genomes tailored for specific applications, Synovance enables manufacturing industries to meet diverse functional requirements across multiple sectors. This innovative approach positions Synovance as a forward-thinking player in the sustainable production of essential goods.

Developer of a microbiome analysis technology designed to monitor the microbiome status and function, and quantify its impact on all aspects of human life. The company offers a benchtop device and microbiome profiling services using optical mapping-based technology, enabling researchers and clinicians to perform strain-level microbiome analysis with high sensitivity, specificity, and reproducibility.

Delmic is a company specializing in correlative light and electron microscopy technology, catering to the needs of life and materials science research. It offers a range of advanced services, including cathodoluminescence, integrated and automated cryo-electron tomography workflows, and rapid electron microscopy solutions designed for reliability and high throughput. By providing integrated correlative microscopy, Delmic equips researchers and organizations with effective and user-friendly tools, enabling them to obtain insights more efficiently and with greater ease.

Synovance is a company focused on the bio-based economy, utilizing plant-derived resources to create a variety of products, including fuels, chemicals, materials, food, and feed. The company specializes in the development of bio-produced textile dyes and engineered organisms that can efficiently convert biomass into these essential materials. By creating customized strains and secondary genomes tailored for specific applications, Synovance enables manufacturing industries to meet diverse functional requirements across multiple sectors. This innovative approach positions Synovance as a forward-thinking player in the sustainable production of essential goods.

Developer of a microbiome analysis technology designed to monitor the microbiome status and function, and quantify its impact on all aspects of human life. The company offers a benchtop device and microbiome profiling services using optical mapping-based technology, enabling researchers and clinicians to perform strain-level microbiome analysis with high sensitivity, specificity, and reproducibility.

Glycanostics is a start-up focused on developing innovative cancer diagnostic tests, specifically targeting prostate cancer. The company specializes in creating clinically validated and registered non-invasive liquid biopsy tests that analyze glycan changes on proteins, such as prostate-specific antigen (PSA). This technology aims to deliver accurate and affordable diagnostic solutions, assisting healthcare professionals in making informed decisions regarding the necessity of biopsies and monitoring patients post-biopsy. Through its advancements in cancer diagnostics, Glycanostics seeks to improve early detection and patient outcomes.

Hoba Therapeutics is focused on developing innovative biopharmaceuticals aimed at treating neuropathic pain and central nervous system disorders. The company is advancing a novel therapeutic protein designed to target specific cells, providing medical practitioners with effective and safe options for managing chronic pain and hearing loss. Through its research and development efforts, Hoba Therapeutics seeks to deliver disease-modifying treatments that enhance the quality of life for patients suffering from neuropathic pain.

Qubit Pharmaceuticals is a Paris-based company established in 2020, focusing on innovative technology for pharmaceutical drug discovery. Founded by prominent academic institutions and researchers, including CNAM, CNRS, the University of Texas at Austin, Sorbonne University, and Washington University, the company leverages over 20 years of research and development. Qubit Pharmaceuticals has developed a drug discovery simulation platform that aims to significantly reduce the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, the platform facilitates virtual screening and visualization of potential drug candidates. By integrating principles of quantum physics, Qubit Pharmaceuticals supports biopharmaceutical companies in accelerating their research and development processes, ultimately enhancing the efficiency of drug discovery.

Deep Branch Biotechnology Ltd., founded in 2018 and based in Nottingham, United Kingdom, specializes in carbon recycling services aimed at creating sustainable food ingredients. The company employs a proprietary gas fermentation platform that utilizes clean and renewable carbon and energy sources to produce bio-based products for the food and feed markets. By focusing on customer-driven research and development, Deep Branch rapidly delivers high-quality ingredients while collaborating with local providers to ensure sustainable input supplies and support local economies. Its approach includes integrating with carbon dioxide suppliers to deploy its technology efficiently, contributing to a reduction in carbon footprints by up to 60% compared to traditional alternatives. This innovative model allows Deep Branch to create locally-produced ingredients that require no arable land and minimal water, effectively addressing climate change and biodiversity loss while ensuring that consumers do not have to compromise on nutrition or quality.

Exeliom is a clinical-stage biopharmaceutical company based in Dijon, France, focused on developing innovative microbial therapies that utilize commensal bacteria as therapeutic agents. Founded in 2016, Exeliom aims to unlock the therapeutic potential of gut microbiota to enhance health and longevity. The company specializes in creating a new class of medicines known as Live Biotherapeutics, which are designed to deliver microbiome-based immunotherapy for conditions such as inflammatory bowel diseases and cancer, with an initial focus on Crohn's Disease. By harnessing the role of microbiota in the immune system, Exeliom strives to provide patients with advanced treatments that improve their quality of life.

LiMM Therapeutics is a biopharmaceutical company focused on developing innovative therapeutic agents aimed at preserving health and addressing inflammatory, infectious, and metabolic diseases. The company leverages the molecular interactions between neuronal cells and innate lymphoid cells to create products that regulate immune responses and combat infections. By bridging advancements in neural sensing and immunology, LiMM Therapeutics aims to unlock new therapeutic solutions that can significantly benefit patients. Its research emphasizes the neuronal-derived regulation of immune cell activity within peripheral tissues, contributing to the development of a robust pipeline of novel treatments.

SiriusXT Limited is a company that specializes in the development and manufacturing of soft x-ray microscopes, specifically the SXT system. Founded in 2015 and headquartered in Dublin, Ireland, SiriusXT's innovative technology utilizes a vacuum-based laser-produced plasma light source to enable high-resolution imaging of biological samples. The SXT system is designed for researchers in disease research and drug discovery, providing a crucial tool for visualizing the 3D internal structures of cells in their native, fully hydrated state without the need for stains or contrast agents. This capability is essential for understanding disease pathways, protein-drug interactions, and bio-engineering processes. SiriusXT is recognized for offering the world's first high-throughput, benchtop soft x-ray tomography system, allowing users to produce detailed tomographs quickly and efficiently.

Ilya Pharma AB, established in 2016 and headquartered in Uppsala, Sweden, specializes in developing biological drugs for treating skin and mucosal wounds. The company's innovative approach involves genetically modifying lactic acid bacteria, commonly found in yogurt, to produce substances that accelerate wound healing. Ilya Pharma focuses on both acute and chronic wounds, with a particular emphasis on addressing the unique challenges faced by diabetic patients.